Press Releases Year None201920182017 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Nov 13, 2019 Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients Nov 12, 2019 Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor Nov 11, 2019 Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results Nov 04, 2019 Turning Point Therapeutics to Host Third Quarter 2019 Conference Call Oct 21, 2019 Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor Sep 30, 2019 Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock Sep 05, 2019 Turning Point Therapeutics Announces Proposed Public Offering of Common Stock Sep 03, 2019 Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor Sep 03, 2019 Turning Point Therapeutics To Participate in Upcoming Investor Conferences Aug 28, 2019 Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 31
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients Nov 12, 2019
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor Nov 11, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor Sep 30, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor Sep 03, 2019
